Table 2.

Summary of genes up-regulated ≥ 2-fold 24 hours post treatment of FSH in GCs transduced with Ad-FOXO1(A3) versus Ad-E (Genes activated by FOXO1 in the absence of FSH)

Gene	Common Name	Fold change (b/a)	FSH + Ad- E Unique reads	FSH + Ad- E RPXM (a)	FSH + Ad- FOXO1(A3) Unique reads	FSH + FOXO1(A3) RPXM  (b)
Bcl2	B-Cell CLL/Lymphoma 2	14.2	19	0.31	48	4.36
Shb	Src homology 2 domain containing adaptor protein B	9.72	7	0.24	44	2.34
Adamts12	Disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 12	7.51	30	0.84	266	6.33
Vgll3	Vestigial-like family member 3	6.98	65	15.16	568	105.79
Ctgf	Connective tissue growth factor	6.7	463	61.95	4151	415.12
Cald1	Caldesmon 1	6.57	658	46.55	6023	305.61
Ets1	v-ets avian erythro- blastosis virus E26 oncogene homolog	4.36	44	2.66	229	121.62
Bdnf	Brain-derived neurotrophic factor	4.27	40	1.85	233	7.9
Fn1	Fibronectin 1	3.75	1926	82.23	9650	308.37
Klf12	Kruppel-like factor 12	3.61	67	1.4	206	5.08
Klf6	Kruppel-like factor 6	3.34	274	8.13	827	27.15
Tgfb2	Transforming growth factor, beta 2	3.03	342	24.99	1449	75.68
Ahrr	Aryl-hydrocarbon receptor repressor	2.99	20	0.62	48	1.85
Cited2	Cbp/P300-interacting transactivator, with Glu/Asp-rich carboxy- terminal domain, 2	2.8	229	42.54	861	119.03
AKAP12	A kinase (PRKA) anchor protein (Gravin) 12	2.66	33	1.37	104	3.66
Fosl2	Fos-like antigen 2	2.6	119	19.47	418	50.7
Rnd3	Rho family GTPase 3	2.56	309	34.67	1099	88.79
Fos	FBJ murine osteo- sarcoma viral oncogene homolog	2.43	13	2.73	42	6.64
Per2	Period circadian clock 2	2.39	28	1.31	86	3.14
Gadd45a	Growth arrest and DNA- damage-inducible, alpha	2.35	38	10.5	119	24.65
Junb	Jun B proto-oncogene	2.32	20	4.06	61	9.41
Rictor	Rapamycin-insensitive companion of mTOR	2.22	176	7.52	498	16.67
Dusp1	Dual specificity phosphatase 1	2.12	60	11.03	170	23.35
WT1	Wilms Tumor 1	2.1	45	4.28	122	8.99
Prkca	Protein kinase C alpha	2.08	82	3.04	244	6.32